Swiss Multi-centre, Randomized, Placebo Controlled Trial of Pregabalin for Prevention of Persistent Pain in High Risk Patients Undergoing Breast Cancer Surgery

Model scores of the 29,894 trials active now.

Model score 10% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (741 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-11-29. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: 30paintypeplacebo controlledinability to
  Phrases that lowered it: patientsparticipantbreaststudy willcreatinine
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Collaborators: 3 (lowers risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Drug's FAERS reports marked serious: 59.9% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Responsible party: sponsor investigator (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 5.9% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 18225 (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 135896 (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• The Effects of Peri-Operative Pregabalin on Post-Operative Pain Following Breast Cancer Surgery With Axillary Node Dissection: A Pilot Study NCT00852683 · started 2008 · scored riskier than 79% of active trials completed
• Perioperative Pregabalin and Lidocaine to Reduce Chronic Breast Cancer Pain NCT02240199 · started 2014 · scored riskier than 44% of active trials completed
• Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel NCT01637077 · started 2012 · scored riskier than 68% of active trials completed
• Perioperative Pregabalin for Reducing Opioid Consumption After Cardiac Surgery NCT04517110 · started 2021 · scored riskier than 27% of active trials terminated
• The Effects of Pregabalin on Postoperative Pain After Cardiac Surgery NCT01701921 · started 2011 · scored riskier than 28% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.